US Patent Litigations are now available. Check here

Explore Idorsia Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 10, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4014976Sep 4, 2024Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)1